C-N4KMAptah Bio
RNA therapeutics, transcription modulation, U1 snRNP
repairingrna therapeutic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-N4KM
C-N4KMC-N4KMRNA therapeutics, transcription modulation, U1 snRNP
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Applications are now... - Teva Pharmaceutical Industries Ltd. Facebook Log In Teva Pharmaceutical Industries Ltd.'s Post Teva Pharmaceutical Industries Ltd. Verified account December 1, 2025 · Shared with Public Applications are now open for Teva Rise! #TevaRise is our global open innovation platform, designed to tackle pharma’s toughest challenges and accelerate solutions that make a real patient impact. We’re calling on startups and innovators who are building transformative solutions to collaborate with us on seven real-world challenges across three key areas: R&D, manufacturing &a
Methytral - On the opening day of ICCE, Methytral... Facebook Log In Methytral's Post Methytral September 17, 2025 · Shared with Public On the opening day of ICCE, Methytral reaffirms its place at the summit of the market, where science meets excellence, and excellence meets leadership. #Methytral #MajesticBiopharma #ICCE2025 #ExcellenceInCare #MarketLeadership +5 All reactions: 178 2 comments 6 shares Like Comment Most relevant Gamal Moselhy بالتوفيق انشاء الله 40w 1 Marwa Ahmed كيفيه الحضور ؟؟ 40w 1
Hear more... - Fargo Moorhead West Fargo Chamber of Commerce Facebook Log In Fargo Moorhead West Fargo Chamber of Commerce's Post Fargo Moorhead West Fargo Chamber of Commerce July 31, 2019 · Shared with Public Hear more from James Brown, VP of Corporate Development, Aldevron, on August 14 at #StateofTech19 ! Aldevron manufactures biological materials, including plasmid DNA, RNA, proteins, enzymes and antibodies, for the biotechnology industry. These products are critical for the discovery and production of many treatments that are in development and on the market today, helping cure dise
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
IVD INDIA | Day 3 at the MedLab Conference was a testament to Biogenix’s unwavering dedication to innovation, collaboration, and excellence
✈️ Amsterdam: Early Access to What’s Not Yet on the Market On June 11–12, the SWC team took part in the Hello Tomorrow Summit 2026 — where scientists, corporations, and the world’s top startups gathered (the top 125 out of 4,500 applicants). For us, this trip was a real test of the current project landscape. We evaluated startups from two angles: 🔍 Anatoly Zhiltsov assessed business model sustainability and how realistic the business case actually was. 📊 Michael Bang checked whether there was genuine market demand. One project that stood out was in the medical field, solving the challenge of
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
ICON Plc - ICON Biotech will be onsite at CTO East Coast,... Facebook Log In ICON Plc's Post ICON Plc June 9 at 7:00 AM · Shared with Public ICON Biotech will be onsite at CTO East Coast, taking place 30 June – 1 July at the Boston Marriott Burlington, MA. As a leading provider of integrated clinical research services, ICON supports oncology and biotech companies across all phases of development, from early planning through late-stage execution. Visit us at Booth #18 and see how ICON Biotech partners with sponsors to address the complexities of drug development through customized solution
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
%PDF-1.4 %���� 15950 0 obj > endobj xref 15950 44 0000000016 00000 n 0000003607 00000 n 0000003774 00000 n 0000006408 00000 n 0000006524 00000 n 0000006578 00000 n 0000007360 00000 n 0000007957 00000 n 0000008120 00000 n 0000008782 00000 n 0000009155 00000 n 0000009622 00000 n 0000009850 00000 n 0000010178 00000 n 0000010512 00000 n 0000010542 00000 n 0000010950 00000 n 0000011076 00000 n 0000011228 00000 n 0000011355 00000 n 0000018359 00000 n 0000018641 00000 n 0000018720 00000 n 0000019603 00000 n 0000020050 00000 n 0000020872 00000 n 0000020986 00000 n 0000021113 00000 n 0000021192 00000 n … b2ede64bf2c xmp.did:efd99aaf-a06d-483b-a845-bc831449ac03 default converted from application/x-indesign to application/pdf Adobe InDesign 20.2 (Macintosh) / 2025-04-24T13:31:21-04:00 application/pdf Adobe PDF Library 17.0 False endstream endobj 1159 0 obj > endobj xref 0 15950 0000000000 65535 f 0000493158 00000 n 0000495053 00000 n 0000497877 00000 n 0000497952 00000 n 0000498256 00000 n 0000498435 00000 n 0000498837 00000 n 0000498896 00000 n 0000500306 00000 n 0000502260 00
EU-Startups - TRIMTECH Therapeutics Limited, a... Facebook Log In EU-Startups's Post EU-Startups 3d · Shared with Public TRIMTECH Therapeutics Limited, a Cambridge-based BioTech company developing new treatments for neurodegenerative diseases, has raised an additional €12 million in Seed funding The financing was led by Johnson & Johnson’s corporate venture capital organisation, Johnson & Johnson Innovation – JJDC, Inc., and BGF, who join existing investors. This brings the total for the round to €41 million – following a previous raise. Dr. Nicki Thompson, CEO, TRIMTECH Therapeut
%PDF-1.4 %���� 4632 0 obj > endobj xref 4632 19 0000000016 00000 n 0000004726 00000 n 0000004889 00000 n 0000006552 00000 n 0000006991 00000 n 0000007163 00000 n 0000007253 00000 n 0000007646 00000 n 0000008140 00000 n 0000009007 00000 n 0000009620 00000 n 0000010220 00000 n 0000010829 00000 n 0000011443 00000 n 0000012082 00000 n 0000012716 00000 n 0000013282 00000 n 0000004476 00000 n 0000000690 00000 n trailer ]/Prev 31391086/XRefStm 4476>> startxref 0 %%EOF 4650 0 obj >stream h��X{TSW��'�"B@c�0EH �h5BL1$NdB�4P�c-�ڊ��C BiP�A �H��hy����V�Б�mkg�k�� u�f����s�Z������}����C8�6H�� … 83B33AAAB3F11F 2012-02-10T00:21:10-05:00 Adobe Illustrator CS5 / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:F87F1174072068118083A2487EC5A84D 2012-02-13T11:28:34-05:00 Adobe Illustrator CS5 / 2012-02-13T11:28:34-05:00 Adobe Illustrator CS5 2012-02-13T11:28:33-05:00 2012-02-13T11:28:34-05:00 application/postscript Said Martinez jo - thin[grey].eps 0 1501 413 1 0 1 1 3000000/10000 3000000/10000 2 1 65535 1501 413 1 False False 360.24 … am H�2P0A= c�l.}�`��b.c=##��.���R�Ҹ �� � endstream endobj 95 0 obj >stream application/pdf GEN_Program_Chart_2021 2023-04-26T14:13:37+02:00 2023-04-26T14:13:37+02:00 2021-01-21T15:55:32-06:00 Adobe Illustrator 25.1 (Macintosh) uuid:fb3c9ea3-e364-1248-a51a-64f05e6a25bd xmp.did:16e89cd7-8192-44ca-8ab5-ec85c45a8e35 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:1fb2e1a1-26d4-b847-8e9d-44a91e0aa20b xmp.did:f5dd99f5-8508-4137-ba7e-18f258074e40 uuid:5D20892493BFDB11914A8 … m H�2P0A= c�l.}�`��b.c=##��.���R�Ҹ �� � endstream endobj 100 0 obj >stream application/pdf GEN_Program_Chart_2021 2023-04-26T14:13:37+02:00 2023-04-26T14:13:37+02:00 2021-01-21T15:55:32-06:00 Adobe Illustrator 25.1 (Macintosh) uuid:fb3c9ea3-e364-1248-a51a-64f05e6a25bd xmp.did:16e89cd7-8192-44ca-8ab5-ec85c45a8e35 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:1fb2e1a1-26d4-b847-8e9d-44a91e0aa20b xmp.did:f5dd99f5-8508-4137-ba7e-18f258074e40 uuid:5D20892493BFDB11914A8 … ���eV ��@��{�n��~`���w�.�qV$�8zz�}`4�/g���>P�?��v��ۭ*5�Cs���;�^[3�]�*RFP ����Q�%Ӭ��"��kfHvK��P�A c�6��g�8�"b��]��kh�}�r�U������ʧ}�Tx��n�9��� �'��a��4S�8w�k2�ހ�kS�����h[T�� R\)J !��К'{�udc���l̍��Н�yE̔J�0 ef���um#�`�̄��]�믏8 �3��1�� ;���ю�h-pq� C��@������0����)* ��Ao:��6���m�N KPtӼI6�E]��I� @��C� l�Z�:C�.�B��k�-�
We’... - Inside Business Today hosted by Bill &Giuliana Rancic Facebook Log In Inside Business Today hosted by Bill &Giuliana Rancic's Post
Fundsforngos - 🚀 Sanofi iNext Moonshot Grants Up to USD... Facebook Log In Fundsforngos's Post Online status indicator Active Fundsforngos January 7 · Shared with Public Sanofi iNext Moonshot Grants Up to USD $500,000 for bold biotech ideas. 18-month R&D journey with Sanofi experts Open to labs & biotech in North America & Europe Focus: Aging-related dysfunction & Targeted delivery of large molecules Apply today https://fundsforcompanies.fundsforngos.org/?p=111889 #HealthcareInnovation #BiotechFunding #Sanofi #MoonshotProjects All reactions: 8 5 shares Like Comment
Speakers | ARDD 2025 Main Past events ARDD 2025 ARDD 2024 XPRIZE Healthspan Team Summit 2024 ARDD 2023 ARDD 2022 About Speakers Speakers 2026 Speakers 2025 Speakers 2024 Speakers 2023 Speakers 2022 Program Main Track Longevity Medicine Track Emerging Science & Technologies Workshop Physics in Aging Biology Startup Pitch Replacement in Aging Workshop Molecular Nutrition Workshop ARDD Tracks Sponsorship Sponsorship Brochure Sponsors 2025 Sponsors 2024 Sponsors 2023 Sponsors 2022 Media Scam Warning Photos Videos Media Kit Photos 2025 Photos 2024 Photos 2023 Photos 2022 Vi … emistry at the University of Copenhagen, Denmark. He was awarded the 2022 Nobel Prize in Chemistry, alongside Barry Sharpless and Carolyn Bartozzi, for the groundbreaking development of ‘Click chemistry and biorthogonal chemistry’. Throughout Meldal’s career, his research has had innovative influences on methods in peptide and combinatorial chemistry. His involvement in method development of solid-phase and combinatorial peptide synthesis, as well as development of the CuAAc … as development of the CuAAc Click reaction, have become mainstream methods for application in bioorganic and organic synthesis. Michael Levitt Department of Structural Biology, Stanford School of Medicine Born in South Africa in 1947, in 1963, I vacationed in London staying to do a BSc degree in physics at Kings College, London.After a pre-doctoral year with Shneior Lifson and his PhD student Arieh Warshel at the Weizmann Institute, Israel, I returned to England in 1968 to s … ographic phase problem. I am increasingly interested in social problems and the application of scientific methods broadly to all walks of life, My ambitions are to enjoy life to the fullest, be a supportive parent and grandparent, work on hard problems and help today’s young scientists gain the recognition and independence my generation enjoyed. Barry Merriman PhD Avery Bio Inc. J. Craig Venter Institute Dr. Merriman has 35 years of experience leading multi-disciplinary R& … iversity College London and Harvard Medical School, he completed a postdoctoral fellowship in Stem Cell Biology and Regenerative Medicine at Stanford University. From 2017-2020, Dr. Duscher was Director of the Research Department for Plastic Surgery at the Technical University of Munich.His research focus is the optimization of cell function in o
Vesper entra em aporte em biotech que busca cura do câncer e do Alzheimer - Estadão E-Investidor Copa 2026 Pulsa Paladar Jornal do Carro Descubra Assine 1 ano por R$ 1,90/mês • Assine 1 ano por R$ 1,90/mês • Entrar Hoje E-Investidor Copa 2026 Pulsa Paladar JC Descubra Notícia Estadão Economia Colunas EXCLUSIVO Coluna do Broadcast Bastidores do mundo dos negócios Seguir Bastidores do mundo dos negócios Vesper entra em aporte em biotech que busca cura do câncer e do Alzheimer Aptah Bio pesquisa correção de erros no RNA que causam doenças neurodegenerativas e câncer PUBLICIDADE Por Cristiane Barb
Stream Podcast 766 – Rafael Bottós: A startup que investe na solução de doenças neurodegenerativas by Podcast Rio Bravo | Listen online for free on SoundCloud SoundCloud JavaScript is disabled You need to enable JavaScript to use SoundCloud Show me how to enable it Podcast 766 – Rafael Bottós: A startup que investe na solução de doenças neurodegenerativas by Podcast Rio Bravo published on 2023-09-08T14:47:55Z A Aptah Bio é uma startup que faz pesquisas voltadas à correção de erros no processamento do RNA, resultando na produção de proteínas tóxicas. Para que se tenha uma ideia, ao se acumulare
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Founded by Lavi Erisson, SFMBA ’19, and... - MIT Sloan Alumni Facebook Log In MIT Sloan Alumni's Post MIT Sloan Alumni February 9 · Shared with Public Founded by Lavi Erisson, SFMBA ’19, and two other MIT alumni, Gensaic uses AI-guided protein design to deliver RNA and other therapeutic molecules to specific cells or areas of the body. Learn more at the link in the comments. All reactions: 2 1 comment Like Comment Most relevant Author MIT Sloan Alumni Link: https://bit.ly/4t6d2Oa NEWS.MIT.EDU Designing the future of metabolic health through tissue-selective drug delivery Designing the fut
List of Biotechnology Companies to Watch – AI Expanded Version Logan Thrasher Collins Subscribe Sign in List of Biotechnology Companies to Watch – AI Expanded Version I used ChatGPT and Claude to expand and revise/update my original 160+ entry list of biotech companies (now at 190 entries). I hope you find this expanded list and its descriptions useful! Logan Thrasher Collins May 02, 2026 10 2 Share Thanks for reading! Subscribe for free to receive new posts and support my work. Subscribe I originally created a list of 160+ companies with detailed descriptions for each one. But updating the li … do so. Relies solely on private funding, thus its investigators do not need to apply for grants and can focus on the research. CRISPR pioneer Keith Joung is one of the first principal investigators at Arena. Aukera [Biomed] Developing protein vault delivery vectors for delivery of peptides, small molecules, and possibly nucleic acids. Their vault formulation is reportedly stable for years at room temperature. Aurora Therapeutics [Biomed] Aurora Therapeutics is building a sca … also predicts compounds which can mimic the protective genomic phenotypes upon application to human cells. Working on preclinical development of drugs for cardiopulmonary and retinal indications as of October 2025. Gameto [Biomed] Developing women’s reproductive health technologies, starting with Fertilo. Fertilo consists of lines of ovarian support cells that secrete hormones to mature eggs in a dish, replacing hormonal injections and shortening the IVF process from 14 days … ude liver, lung, and central nervous system. As of June 2023, has raised $3.5M (grant from Cystic Fibrosis Foundation). Gordian Biotechnology [Biomed | Bio-AI] Gordian Biotechnology uses pooled in vivo screening to discover therapies for complex age-related diseases. Its Mosaic Screening approach tests many candidate therapies in disease-relevant animals, while computational analysis helps identify interventions most likely to translate to humans. Grove Biopharma [Biomed] Has … eness (RXE) and Target Animal Safety (TAS) sections of its conditional approval application; the manufacturing section remains. The pivotal STAY field study of LOY-002 enrolled ~1,300 dogs across ~70 US clinics and completed enrollment in mid-2025. LyGenesis [Biomed] Allogenic cell therapy that uses host lymph nodes as bioreactors to grow ectopic
Life Biosciences has been named one of... - David A. Sinclair Facebook Log In David A. Sinclair's Post David A. Sinclair April 27 · Shared with Public Life Biosciences has been named one of TIME’s 10 Most Influential New Frontiers Companies of 2026, along with IBM and SpaceX This reflects years of work by a dedicated and focused team From left to right: Dr. Michael Ringel (COO), Dr. Sharon Rosenzweig-Lipson (CSO), and Jerry McLaughlin (CEO). Not pictured: Amit Shashank (CAO), Ivan Kaplan (VP General Counsel) and my co-founder and founding CEO, Tristan Edwards Grateful to the scientists, c
Hello Tomorrow Global Summit 2025 | Teaser | 10th Edition | Aptah Bio LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement ,
Revised criteria for diagnosis and staging of... : Alzheimer's & Dementia Ovid ® Beta Ovid Logo Search Ovid Search Ovid Alzheimer's & Dementia Navbar Menu Current Issue Previous Issues Latest Articles More menu items Search Journal Search Journal Button group. Outline PDF Share Cite Permissions RESEARCH ARTICLE Revised criteria for diagnosis and staging of Alzheimer's disease Alzheimer's Association Workgroup Clifford R. Jack J. Scott Andrews Thomas G. Beach Teresa Buracchio Billy Dunn Ana Graf Oskar Hansson Carole Ho William Jagust Eric McDade Jose Luis Molinuevo O … standard should be used for clinical diagnostic purposes, and the same criteria apply to PET, CSF, or blood‐based biomarkers. We recommend, as a minimum requirement, an accuracy of 90% for the identification of moderate/frequent neuritic plaques at autopsy (or an approved surrogate, which, at this point, would be amyloid PET or CSF) in the intended‐use population. For blood‐based biomarker assays, this translates to an accuracy equivalent to that of approved CSF assays. We fo … ent Clinical judgement must always be used in the practice of medicine, and the application of diagnostic tests for AD is no exception. Limitations of currently available biomarkers (Box 3) underscore the importance of clinical judgment when used clinically. BOX 3: Limitations of biomarkers Lack of certified biofluid reference methods and materials (except for cerebrospinal fluid [CSF] amyloid beta [Aβ]42, where these are available). Biomarkers (positron emission tomography [ … whom the disease has been diagnosed by means of Core 1 biomarkers and does not apply to individuals who are not in the AD pathway. We structured this document to reflect this (i.e., diagnosis is the first step and only then does staging of AD become relevant). 4.1 Approaches to biological staging In the 2018 framework, the “plus/minus” combinations of AT(N) were used as an informal staging scheme; individuals in the AD continuum were expected to progress from A+T−N− to A+T+N … tion he has recieved funds from the National Institutes of Health for reviewing grant proposals. He also has a leadership/fiduciary role and stock options with Vivid Genomics. Teresa Burracchio is employed by the US Food and Drug Administration and has no financial conflicts to disclose. Billy Dunn is a consultant and has received consulting fees
Brazilian Biotech Innovators Prepare for the Global Stage | Next Phase Newsletter Life Science Nation Next Phase Newsletter Search Next Phase Newsletter Home Hot Mandates Previous Issues Podcast Subscribe Brazilian Biotech Innovators Prepare for the Global Stage 6 Jun By Karen Deyo , VP of Product, Israel BD, LSN ApexBrasil and Abiquifi , government and pharma organizations in Brazil, worked together to hand-pick 10 startups to represent the amazing Brazilian innovation ecosystem in the life sciences at BIO this week. Brazil is making an effort to bring their technologies abroad, and each … offices throughout Asia, New York, and San Diego. The firm has closed its fifth fund in 2017 and is currently raising a sixth fund, which the firm is targeting to be the largest fund to date. The firm continues to actively seek investment opportunities across a […] LSN Twitter Tweets by LSciNation Follow Next Phase Newsletter on WordPress.com Contact us +1 (617) 600-0668 [email protected] Archives Archives Select Month June 2026 (17) May 2026 (26)
John F. Crowley, President and CEO of the Biotechnology Innovation Organization - BIO, representing biotech companies and organizations worldwide, delivered a powerful keynote to over 2,000 leaders from across the global neuromuscular community at the 2026 MDA Clinical & Scientific Conference in Orlando, Florida. In his address, “Driving the Future of Innovation, Policy, and Patient Impact,” Crowley highlighted how biotechnology innovation, patient-driven advocacy, and cross-sector collaboration are accelerating transformative therapies and expanding access for people living with rare and
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Ericks Sousa - Principal Researcher - Biochemistry at APTAH Biosciences | The Org Platform Enrich Pricing Log in Sign up APTAH Biosciences Ericks Sousa Unverified Ericks Sousa Principal Researcher - Biochemistry Contact Ericks Sousa, PhD, holds a PhD in Pharmacology from the Federal University of Santa Catarina, where they also completed a Master's degree in the same field. They were a visiting student at the University Medical Center Göttingen in Germany and earned a Bachelor's degree in Biological Sciences from the Federal University of Pará. Currently, Ericks is a Principal Rese
Albert Einstein College of Medicine welcomed more than 100 attendees to its inaugural Start-Up Showcase, marking an exciting milestone in the institution’s continued growth in commercialization and innovation. The event brought together biotech companies built on Einstein discoveries with potential investors, industry leaders, faculty, board members, and alumni. Seven high-potential start-ups took the stage, each presenting novel therapies and platforms—many already advancing into clinical trials. From cancer and autoimmune immunotherapies to innovative drug delivery approaches, the showcase r
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Breakthroughs in gene therapy begin with the right partnerships! 🧬 We’re thrilled to announce a new partnership between DKSH Technology Taiwan and Helix Biotech, a nanobiotechnology company specializing in lipid nanoparticle formulation and scalable manufacturing solutions, to support market development in Taiwan. As the exclusive partner, DKSH provides integrated Market Expansion Services including commercialization, distribution, and technical support, enabling academia and biotech institutions to access lipid nanoparticle technologies for mRNA delivery and nucleic acid therapeutics. This c
🌟 Showcasing innovation on a global... - New to the Street Facebook Log In New to the Street's Post New to the Street 2d · Shared with Public Showcasing innovation on a global stage. Medicus Pharma Ltd. (NASDAQ: MDCX) will highlight its SkinJect® registrational strategy and Teverelix® precision medicine program at BIO International 2026, one of the biotechnology industry's premier events. The presentation underscores the company's commitment to advancing innovative therapies and accelerating clinical development through precision medicine. READ HERE https://bit.ly/MedicusPharma
ICON Plc - ICON Biotech is sponsoring #OCTUK26, taking... Facebook Log In ICON Plc's Post ICON Plc June 5 at 2:00 AM · Shared with Public ICON Biotech is sponsoring #OCTUK26 , taking place 9–10 June in London. Visit us at booth #42 to learn how we’re advancing clinical trial solutions through innovation, operational excellence and deep therapeutic expertise. From streamlining operations, to navigating complex regulatory landscapes, our team supports the full journey of clinical development. https://ow.ly/Goqa50YBeli All reactions: 2 Like Comment
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Radar, TTR Data - TTR Data - M&A, PE, VC, Capital Markets, Financial Database --> Dashboard Dashboard Mergers & Acquisitions Fixed Income Radar Radar Transactions Transactions EQUITY TRANSACTIONS Mergers & Acquisitions Private Equity Venture Capital Asset Acquisitions Joint Ventures Equity Capital Markets DEBT TRANSACTIONS Project Finance Acquisition Finance Transactions Map Transaction Types Definitions Transaction Inclusion Criteria How Transaction Values are Calculated Rankings / League Tables Rankings / League Tables Advisory Rankings Mergers & Acquisitions Private Equity / Venture Cap
MilliporeSigma - Congratulations to Stemmatters, winner of... Facebook Log In MilliporeSigma's Post MilliporeSigma November 6, 2025 · Shared with Public Congratulations to Stemmatters, winner of our Advance Biotech Grant Program! Their mimsys® biomaterial platform helps address challenges in cell and gene therapy manufacturing, accelerating how life-saving therapies reach patients. Our runners-up, Troya Therapeutics and Mesenbio, are developing novel approaches that open up new possibilities for treating disease. Biotech innovation is reshaping how future therapies are discovered, develop
We’... - Inside Business Today hosted by Bill &Giuliana Rancic Facebook Log In Inside Business Today hosted by Bill &Giuliana Rancic's Post Inside Business Today hosted by Bill &Giuliana Rancic Verified account May 14 · Shared with Public We’re excited to announce the upcoming airing of VoxCell’s feature story on Inside Business Today. Voxcell develops physiologically relevant 3D vascularized human tissue models designed to help accelerate drug development and advance personalized medicine. Their innovative platform is helping bring more relevant, human based insights to the f
Program | ARDD 2025 Main Past events ARDD 2025 ARDD 2024 XPRIZE Healthspan Team Summit 2024 ARDD 2023 ARDD 2022 About Speakers Speakers 2026 Speakers 2025 Speakers 2024 Speakers 2023 Speakers 2022 Program Main Track Longevity Medicine Track Emerging Science & Technologies Workshop Physics in Aging Biology Startup Pitch Replacement in Aging Workshop Molecular Nutrition Workshop ARDD Tracks Sponsorship Sponsorship Brochure Sponsors 2025 Sponsors 2024 Sponsors 2023 Sponsors 2022 Media Scam Warning Photos Videos Media Kit Photos 2025 Photos 2024 Photos 2023 Photos 2022 Vid … gratitude 4 years into longevity investing: Takeaways deploying an early stage fund Sergey Jakimov 20:00-20:15 Break 20:15-20:55 Investor Panel-Early Stage Tom Zuber Moderator Zuber Lawler Garri Zmudze LongeVC William Harborne LongGame Anne Marije van Harten Apollo Health Ventures 21:00-21:40 Investor Panel-Growth Stage Tom Zuber Moderator Zuber Lawler Murali Venkatesan Danaher Corporation Kitsu Egerton Baillie Gifford Daisy Cai B Capital August 25 August 26 August 27 August … 08:00-09:00 Registrations, coffee, tea 09:00-09:15 Welcome and Poster + Travel Grant Award ceremony 09:10-09:30 Organ Protection with GLP-1 Receptor Agonists Lotte Bjerre Knudsen Novo Nordisk 09:30-09:50 BioAge Labs Sponsor talk - with gratitude Novel NLRP3 inflammasome inhibitors: From structural discovery to clinical trial Rusty Montgomery 09:50-10:10 A new, translational paradigm for pre-clinical drug testing Steve Austad University of Alabama Birmingham 10:10-10:30 Coffe … exercise Bente Klarlund University of Copenhagen 11:30-13:00 Lunch and Startup Award ceremony 13:00-13:20 Endogenous amyloid beta promotes spontaneous brain aging and learning loss in turquoise killifish Dario Riccardo Valenzano Leibniz Institute on Aging 13:20-13:40 Deep Origin Sponsor talk - with gratitude Towards Integrated Multi-Level Physics and ML for Aging and Drug Discovery Michael Antonov 13:40-14:00 Telomeres, Transcriptomes and Troubles: Bats as new models of exte
Members | Longevity Biotechnology Association About Members Collaborators News Contact Donate Our members make us Nir Barzilai Founding Director of the Institute for Aging Research at the Nathan Shock Center of Excellence in the Basic Biology of Aging. Director of the Paul F. Glenn Center for the Biology of Human Aging Research at Albert Einstein College of Medicine. Andre Bertram Co-Founder of Beyond Aging, an organization dedicated to growing the funding environment for longevity research, and CEO of Helpwear, a medical device company building emergency cardiac monitoring devices. Joe Betts- … Co-Founder & Managing Director at Apollo Health Ventures, a venture capital fund that invests in early-stage biotech and aging biology companies. Daisy Robinton Co-Founder and CEO of Oviva Therapeutics, Director of Women's Health at Cambrian Biopharma. Hillel Roth Scientist and entrepreneur whose scientific contributions include some of the most widely used tools for RNA editing. CSO and co-founder of Aevum Labs, a company founded to radically extend humanity’s healt … y lifespans of at least one billion people. Co-Founder of BOLD Longevity Growth Fund. Innovation Board Member at XPRIZE Foundation, Development Sponsor of the Healthspan XPRIZE. Alex Zhavoronkov Current Founder and CEO of Insilico Medicine, and founder and former CEO of Deep Longevity. Garri Zmudze Garri Zmudze is an investor and advisor for deeptech companies developing life-changing solutions across biotech, medicine, longevity and more. Garri is committed to building a wor
Several medical products from... - Suzhou Industrial Park Facebook Log In Suzhou Industrial Park's Post Suzhou Industrial Park Verified account January 15 · Shared with Public Several medical products from #SIP have received approval from the National Medical Products Administration. Approved for marketing: • Baiyueda® (sonrotoclax tablets) for blood cancer by BeOne Medicines Approved for a pilot segmented-production program: • Zamerovimab and Mazorelvimab Injection for rabies by Synermore Biologics Looking forward to more innovations from SIP's biomedicine companies! All reactions:
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
AstraZeneca - Mene Pangalos, Executive VP of the IMED... Facebook Log In AstraZeneca's Post AstraZeneca Verified account September 23, 2017 · Shared with Public Mene Pangalos, Executive VP of the IMED Biotech Unit, has invaluable experience as a member of multiple Boards of Directors throughout the U.K. Learn about his latest initiatives: https://goo.gl/qJS3n4 All reactions: 19 Like Comment
Press releases | Harnessing the power of RNA epigenetics | Cambridge, UK | STORM Therapeutics Platform RNA modifying enzymes Publications Clinical trials STC-15 About us Leadership team Board members Investors News Press releases STORM in the News Contact LinkedIn Twitter Press releases 22nd May 2026 STORM Therapeutics to Present Promising Phase 1 Sarcoma Data Demonstrating Activity of First‑in‑Class METTL3 Inhibitor STC‑15 at ASCO 2026 Subset analysis shows early clinical activity supported by biomarker evidence of targeting cancer stem cell pathways driving tumor growth and progression Read
Exhibitors and Sponsors You need to enable JavaScript to run this app. This site is part of the Informa Connect Division of Informa PLC Informa PLC About Us Investor relations Talent This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. November 9–11, 2026 Koelnmesse Cologne, Germany Home home Ways to attend expand_more Registration Options Company Presentation Options Delegations Program expand_more 2026 Agenda Agenda I
STORM Therapeutics and AlidaBio Announce Strategic Collaboration to Accelerate Development of Cancer Therapies Targeting RNA Modifications Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overvie … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Copy of ARDD 2026 Main Past events ARDD 2025 ARDD 2024 XPRIZE Healthspan Team Summit 2024 ARDD 2023 ARDD 2022 About Speakers Speakers 2026 Speakers 2025 Speakers 2024 Speakers 2023 Speakers 2022 Program Main Track Longevity Medicine Track Emerging Science & Technologies Workshop Physics in Aging Biology Startup Pitch Replacement in Aging Workshop Molecular Nutrition Workshop ARDD Tracks Sponsorship Sponsorship Brochure Sponsors 2025 Sponsors 2024 Sponsors 2023 Sponsors 2022 Media Scam Warning Photos Videos Media Kit Photos 2025 Photos 2024 Photos 2023 Photos 2022 Video … uotes Really enjoyed the breadth of talks and discussions. Michael Levitt Nobel Prize in Chemistry 2013 Stanford Phenomenal conference in the Rejuvenation Field. Steve Horvath Principal Investigator Altos Lab Where one can learn about aging scientifically, clinically and in real life. Xingli Wang Fosun Global Partner Fosun Pharma The ARDD event pioneers the future of healthy aging, driving breakthroughs in longevity research while opening a new era of cosmetic innovation Luc … ming and hearing about transformative technologies in the workshops. And Alex’s proposal to Dominika most memorable! Adam Antebi Max Planck Institute for BIology of Ageing, Cologne, Germany We are at a pivotal moment. The stars have aligned to make real progress in understanding aging and ultimately extending longevity. I found ARDD to be the nexus where diverse perspectives converge, accelerating this progress. Albert-László Barabási Northeastern University Attending for the
%PDF-1.4 % ���� 3 0 obj > /PageLabels > ] >> /Outlines 2 0 R /Pages 1 0 R >> endobj 4 0 obj > endobj 5 0 obj > >> endobj 6 0 obj > stream x���n1��(�j�$�����Q�Ca� � ��&�6-)H�y��o�Kqaƛͺ�*��������x : �po��% Õ(�6{�~\�YX|�����I;/�b����(~�Wl��$.��bq}�fu����� 3��yR ^�~��5E�I �G*#��K�T�ƻ �a�M�`�0�hR ar� �:�ɪC²x뜲��Xv��f�u%bp&De!����dk��d^QfK�v�5t.�A�0yD !��R�p�I���=l���p��VE�zS�CIu)cMYT�E�v��2o����ywjǙP�c '���^���?������l�d��ug �L�fm���f���V�*��_3è�1�D{͒��(c2� �E�O,}ш@s�W�W�� ʂ������z��䁦���s8��d�?� ��| } }���o�;�f|� �� �A3�Z9]M(��U7I��A��]h.u�߄���'��q� endstream endob … �h6�vO���f4۵��~���}U�jV:E��ڭ����X�..eX�L�Y�$��"�E���EO�F4���u��7�&���h�rFp' r �����^3�[���:���-d!c�!A�������d�������(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(��(���V��qp�!��9 �N0$�{U )�gr�' ).��V�5���[�9��~�~?�q��A �8�[��q��R]OըՍjq� ��QEF�EPWWZZ�qp�!� ��' I����+��'j˦�^xVM�7��� T���nFGB��^^Na;�G�� �}B�
Falling Walls - 🧬 The next breakthrough therapy could come... Facebook Log In Falling Walls's Post Falling Walls March 5 · Shared with Public The next breakthrough therapy could come from your lab As part of the Falling Walls Global Call 2026, Falling Walls Venture, in partnership with Boehringer Ingelheim , is looking for biotech start-ups turning scientific discoveries into therapies and platform technologies with real clinical impact. If you know a biotech start-up that interested in pitching to our international audience of investors and industry leaders, nominate them here: https:/
We... - Federation of European Neuroscience Societies (FENS) Facebook Log In Federation of European Neuroscience Societies (FENS)'s Post Federation of European Neuroscience Societies (FENS) June 16 at 1:02 AM · Shared with Public We are proud to present #FENS2026 Silver sponsor: RWD Life Science! For over 20 years, RWD Life Science has been driving R&D innovation delivering cutting-edge solutions across: Neural research & imaging Animal surgery & modelling Cell/molecular biology Behavioural analysis Diagnostics & histopathology Learn more about them at www.rwdstco.com and
BIO Partnering™ for Oncology Spotlights - BIO Partnering for Oncology 2026 Skip To Main Content Home About BIO BIO Partnering™ Show submenu for: BIO Partnering™ Participating Companies Spotlight Companies LOG IN TO BIO PARTNERING Sponsor Contact Us More Show more menu items Home About BIO BIO Partnering™ Show submenu for: BIO Partnering™ Participating Companies Spotlight Companies LOG IN TO BIO PARTNERING Sponsor Contact Us More Show more menu items Home About BIO BIO Partnering™ Show submenu for: BIO Partnering™ Participating Companies Spotlight Companies LOG IN TO BIO PARTNERING Sponsor Cont … ent by 5x while maintaining US FDA standards. Furthermore, through our deeptech fund SeaX Ventures, we offer the unique advantage of potential follow-on funding from our Fund III for companies that demonstrate favorable clinical outcomes." Kid Parchariyanon Managing Partner SeaX Ventures Kaida BioPharma "During BIO Partnering for Oncology, our goal at Kaida Biopharma is simple: build the right partnerships that move new options forward for women w
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Vesper Ventures | Portfolio, Investments & AUM | Caplight NEW Caplight raises a $16M Series A, led by BlackRock and Fin Capital → Products Solutions Resources Log in Book a demo Investors Vesper Ventures Vesper Ventures Florianópolis, Santa Catarina vesper-bio.com Overview Vesper Ventures is a venture builder and venture capital firm based in Florianópolis, Brazil, that focuses on creating and investing in early-stage, disruptive biotechnology companies. The firm invests in sectors including human health, agriculture, therapies, and diagnostics. Year Founded 2015 Portfolio Companies 2 Webs
%PDF-1.4 %���� 2378 0 obj > endobj xref 2378 45 0000000016 00000 n 0000004035 00000 n 0000004198 00000 n 0000006270 00000 n 0000006385 00000 n 0000007031 00000 n 0000007809 00000 n 0000007861 00000 n 0000007912 00000 n 0000007963 00000 n 0000008014 00000 n 0000008127 00000 n 0000008401 00000 n 0000009368 00000 n 0000009763 00000 n 0000010133 00000 n 0000010498 00000 n 0000010966 00000 n 0000011535 00000 n 0000011903 00000 n 0000011988 00000 n 0000016816 00000 n 0000023817 00000 n 0000109973 00000 n 0000129839 00000 n 0000130317 00000 n 0000152672 00000 n 0000290012 00000 n 0000419896 00000 n 0 … �G��X࣒X*M�}Tw海il�w�k��s�nt@���/����� �� endstream endobj 2419 0 obj >stream application/postscript particle style cyber network visualization wallpaper with text space Akash abstract particle tech technology digital data science web futuristic network system internet research innovation ai artificial intelligence cyber dynamic wallpaper visualization connectivity information background banner design concept net techno dot dotted blue particle style cyber network visualiza … 2023-05-24T15:15:46+05:30 Adobe Bridge 2022 (Windows) /metadata converted from application/postscript to application/vnd.adobe.illustrator Basic RGB 1 True False 49.180556 17.652778 Inches Cyan Magenta Yellow Black Default Swatch Group 0 White RGB PROCESS 255 255 255 Black RGB PROCESS 0 0 0 Adobe PDF library 15.00 endstream endobj 2420 0 obj > endobj 1 0 obj >/Font >/ProcSet[/PDF/Text]/XObject >>>/Rotate 0/StructParents 1/TrimBox[0.0 0.0 496.063 612.283]/Type/Page/PieceInfo … ���pi��&���~�P\ -��D a%�A]��\��T�h���.��]�xY�:�� ��L���H�,��f w��{IrFp���s��)�����D��ɉy�&��m�L�ե�O�/�׳D� �����)����2� x�-dw�*~�3�e�` �og����}�c�gH������z�Q^?�ˣ"��.9�yt��:Mn'�I���e,KZ��G$G�� ���9�"��6� �b �顳����ķ����j�Vdi! ���L�� ����M�����Vq�f���EKi�i�4�g��� 3�M/h���M]�A!��� �}�=��ӟ\g=�C��]Xuk4��kh=,Yî�'#�{c|�~Hnk�V��!�Y �������Ж�̬�U�7s PN��ZU����>π�NeY go& k�Ѥ �!��8�t�f(��^�I��ᵞWޝ�qh%�k �܈� �ڂړRPV���i�����!���ȣD�Hɹli[��\�� … Э������Q {{\��� v|�����_����?��������g�Y endstream endobj 207 0 obj >stream application/postscript particle style cyber network visualization wallpaper with text space Akash abstract particle tech technology digital data science web futuristic network system internet research innovation ai artificial intelligence cyber dynamic wallpaper visua
We are proud to announce our strategic partnership with Station F, the world's largest startup campus. As the first biopharma company to launch such a comprehensive program, this unique collaboration is aimed at accelerating AI-powered R&D and leading the development of a groundbreaking "digital immune system." We're inviting innovative, early-stage health-tech and biotech startups from around the globe to join us. This is an opportunity to gain access to Sanofi's scientific expertise, proprietary data, and mentorship, combining your fresh entrepreneurial energy wi … ady to make a real impact? True transformation happens together. Learn more and submit your application today: http://spkl.io/6189AFWHX #STATIONF #AI | Sanofi
%PDF-1.7 %���� 470 0 obj > endobj xref 470 34 0000000016 00000 n 0000002640 00000 n 0000002771 00000 n 0000004081 00000 n 0000004724 00000 n 0000005464 00000 n 0000005723 00000 n 0000005760 00000 n 0000005874 00000 n 0000006758 00000 n 0000007519 00000 n 0000008390 00000 n 0000009246 00000 n 0000010113 00000 n 0000010955 00000 n 0000011440 00000 n 0000011527 00000 n 0000012017 00000 n 0000012272 00000 n 0000012860 00000 n 0000013394 00000 n 0000013887 00000 n 0000014744 00000 n 0000015032 00000 n 0000015951 00000 n 0000030514 00000 n 0000071021 00000 n 0000073670 00000 n 0000077778 00000 n 000 … b0ae4b2ea32 xmp.did:af412893-97ac-4854-b3b7-5bcd629f0750 default converted from application/x-indesign to application/pdf Adobe InDesign 20.0 (Macintosh) / 2024-11-05T18:57:00-03:00 application/pdf Adobe PDF Library 17.0 False endstream endobj 469 0 obj > endobj xref 0 470 0000000000 65535 f 0000081788 00000 n 0000082833 00000 n 0000085348 00000 n 0000086573 00000 n 0000090199 00000 n 0000091292 00000 n 0000095629 00000 n 0000096534 00000 n 0000103172 00000 n 0000109942 00000
The 6 shortlisted... - Royal Society of Chemistry Facebook Log In Royal Society of Chemistry's Post Royal Society of Chemistry June 18 at 5:35 AM · Shared with Public The 6 shortlisted technologies in the Health category are from AlphaVectors Biotech, ConsoneAI Ltd, Microsol Ltd, Molecular Titans Ltd, and University of Bath. https://rsc.li/49OtMSf +3 All reactions: 6 Like Comment
MBC BioLabs | Portfolio, Investments & AUM | Caplight NEW Caplight raises a $16M Series A, led by BlackRock and Fin Capital → Products Solutions Resources Log in Book a demo Investors MBC BioLabs MBC BioLabs San Francisco, California mbcbiolabs.com Overview MBC BioLabs is a biotech incubator that provides lab space and operational support for early-stage biotech companies . The company offers access to equipment and a community to facilitate the development and launch of biotech innovations, primarily serving the biotech sector . Year Founded 2013 Portfolio Companies 7 Website mbcbiolabs.c … Website mbcbiolabs.com Investments Company Date Stage Lead DeepSeq.AI May 2025 Grant Co-investor Aptah Bio Aug 2023 Series A Co-investor Deciduous Therapeutics Oct 2021 Grant Co-investor Aptah Bio Aug 2021 Accelerator Co-investor Asher Biotherapeutics Mar 2021 Series A Co-investor View all investments Sector & Stage Mix Industry, funding stage, and valuation band breakdowns. Premium Seed Series A Series B Growth Unlock portfolio analytics Sign up to view full sector, sta
Aptah Bio secures $3M grant for oncology and ophthalmology research | Rafael M. Bottos posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or s … n Top Content People Learning Jobs Games Join now Sign in Aptah Bio secures $3M grant for oncology and ophthalmology research Rafael M. Bottos 1y Report this post 🚀 Exciting News from Aptah Bio! 🚀 We are thrilled to announce that Aptah Bio has secured a $3M non-dilutive grant to accelerate groundbreaking research in oncology and ophthalmology! This funding will complement our ongoing Series A round, supporting the development of our lead compound (APT20TTMG) and advancing i … . Biopticka will serve as a reference site for AIxMed in Europe, showcasing the application of AIxURO™ to potential partners and clients. The collaboration aims to expand into other cytology applications through research, clinical validation, and co-authored publications. Read more: https://lnkd.in/gsppJNVp 📰 Subscribe to the Life AI Weekly Newsletter: https://lnkd.in/eC5-u69w #ai #artificialintelligence #ainews #aifunding #biotech #healthcareai 2 Like Comment Share Copy Lin
Biotech Venture Capital Activity in Brazil Home About Meet the Team Hidden Layers Podcasts Nucleate Search Join Ecosystem Reports Hidden Layers Articles Biotech Venture Capital Activity in Brazil Brazilian VC funding in biotech is on the rise, with approximately 50 firms investing in a diverse range of biotech sectors. Lauren Stanwicks and Romina Soledad Horianski May 28, 2024 — 9 minutes read Highlights: Brazilian VC funding in biotech is on the rise, with approximately 50 firms investing in a diverse range of biotech sectors. Top players like GRIDS Capital, Vesper Ventures, and LifelyV … os, and LifelyVC. Top Funds Top three Brazilian VC funds GRIDS Capital , with a fund size of $161.1 million, was founded in 2016 and is headquartered in Sao Paulo. It operates as a deep tech venture capital firm, with investments spanning various sectors including AI, Robotics, Life Sciences, Tech Infrastructure, Energy, and Advanced Materials. While ranking first in biotech investments, this sector constitutes approximately 10% of their overall investment portfolio. Notable … unded in 2018 and based in Florianopolis, operates as a biotech-focused venture fund and venture builder. While ranking second in the number of biotech investments, all of its investments are focused on the biotech sector. Besides investments in companies such as Symbiomics, Cellertz Bio, and InEdita Bio, Vesper Ventures has recently invested in agriculture biotechs Hapiseeds and Reddot Bio. Aptah Bio, one of their portfolio companies, is a Brazilian biotech specializing in R … g Funds Although not among the top five firms, Green Rock, a healthcare-focused fund established in 2017, has started investing in biotech companies like NAIAD Drug Development and miRscience Therapeutics. MiRscience Therapeutics, a Brazilian seed-stage biotech company, specializes in developing artificial microRNAs to target aging diseases like sarcopenia (muscle loss) using their patented MIR-discovery platform. These investments are not yet reflected in Crunchbase's datase … ite the growing numbers and excitement on AI in Biotech, most of the technology application is still in its preclinical stages, having yet to prove itself. Figure 6. Areas of focus of 61 companies invested in by Brazilian Venture Capital Firms Figure 7. Technological assets of 61 companies invested in by Brazilian Venture Capital Firms Take
Aptah Bio | RNA Therapeutics to Slow Cancer Evolution
Aptah Bio | RNA Therapeutics to Slow Cancer Evolution
Aptah Bio | RNA Therapeutics to Slow Cancer Evolution
RNA Rejuvenation Technology - Aptah Bio Inc | Rafael M. Bottos LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privac
Aptah Bio, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Aptah Bio, Inc. Startups | Private Company | 2020 | California, United States | < 10 | www.aptah-bio.com Startups | Private Company | 2020 | California, United States | < 10 | www.aptah-bio.com Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Nervous System Diseases Other Diseases Neoplasms Chemical drugs Disease domain score A glimpse into the focused … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Aptah Bio Inc. | BIO-Europe You need to enable JavaScript to run this app. This site is part of the Informa Connect Division of Informa PLC Informa PLC About Us Investor relations Talent This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. November 9–11, 2026 Koelnmesse Cologne, Germany Home home Ways to attend expand_more Registration Options Company Presentation Options Delegations Program expand_more 2026 Agenda Agen
Brazilian scientists may have found cure to Alzheimer - Peq42 Skip to content Home Account Blog Renders NSFW SFW Games & Projects Forums Commissions Search for: Brazilian scientists may have found cure to Alzheimer Posted on 26/12/2023 26/12/2023 by peq42 A Brazilian biotechnology startup has created a molecule capable of revitalizing and restoring human neurons through RNA therapies. The groundbreaking outcome, achieved by Aptah Bio , emerged from trials conducted in Canada, involving cells from the central nervous system of both healthy elderly individuals and those with Alzheimer’ … irman of the Board. As part of the Vesper Ventures portfolio, a venture builder fund focusing on advanced biotechnology, the startup is positioned for further growth. Source: Olhar Digital Post navigation Previous: Brazil is finishing another Nuclear Plant Next: Being Indie is difficult Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Latest Blog posts> Nearly 400 Newspapers Sue OpenAI and Mi
Aptah Bio Inc. | BIO-Europe Lead Retrieval You need to enable JavaScript to run this app. This site is part of the Informa Connect Division of Informa PLC Informa PLC About Us Investor relations Talent This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. November 3–5, 2025 Vienna Congress and Convention Center, Vienna, Austria November 11–12, 2025 | Digital Partnering Home home What to expect expand_more Get event broch
Aptah Bio Inc. | Upgrade to All-Access with Epp You need to enable JavaScript to run this app. This site is part of the Informa Connect Division of Informa PLC Informa PLC About Us Investor relations Talent This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. Europe's premier partnering event November 4–6, 2024 | Stockholm, Sweden November 12–13, 2024 | Digital Partnering Home home Program expand_more Agenda Plan Y
Aptah Bio | RNA Therapeutics to Slow Cancer Evolution
Aptah Bio | RNA Therapeutics to Slow Cancer Evolution
Aptah Bio | RNA Therapeutics to Slow Cancer Evolution
Aptah Bio | RNA Therapeutics to Slow Cancer Evolution
Aptah Bio Receives Orphan Drug Designation for Glioblastoma Program | Rogério Vivaldi, MD, MBA posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to j … NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 6. Vogel JD, Felder SI, Bhama AR, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Colon Cancer. Dis Colon Rectum. 2022;65(2):148-177. …more 63 1 Comment Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Dimitrios Stylianakis 2
Aptah Bio selected as finalist at Hello Tomorrow Summit | Aptah Bio posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree t … ng care delivery. As investors, our role is not only to follow momentum, but to fund the breakthroughs that matter. Invest in science with empathy and strategy. The cycle always rewards conviction. #HealthcareInnovation #Biotech #LifeSciences #VentureCapital #MedTech #DigitalHealth #InvestmentStrategy #AI 4 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in 2,892 followers View Profile Connect Explore related topics How Immunotherapies Are Changing
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Aptah Bio — Whiteford Research Biobase Company DB ← Company DB Company information is AI generated, and may be inaccurate. Aptah Bio Overview Aptah Bio is a San Carlos, California biotechnology company developing RNA therapeutics for cancer and age-related disease biology, with public materials describing the company as a for-profit private company founded in 2019 and headquartered at MBC BioLabs in San Carlos, CA. [1] Its current website frames the company around slowing tumor evolution by reducing cancer-cell variability and making aggressive cancers more predictable and treatable. [2] Publi
#dementia #cancers #aptahbio #longevity | Aptah Bio LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy ,
It starts today! I'm proud to join leading minds in the Longevity field at the Longevity Investors Conference at Gstaad, Switzerland. I will be presenting Aptah Bio science and investment… | Rafael M. Bottos LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any
Aptah Bio | Valuation, Funding Rounds & Stock Price | Caplight NEW Caplight raises a $16M Series A, led by BlackRock and Fin Capital → Products Solutions Resources Log in Book a demo Companies Aptah Bio Aptah Bio Private San Carlos, California Healthcare & Life Sciences https://www.aptah-bio.com/ Last Round Seed Dec 24, 2024 Total Funding Raised $18M Company Overview Aptah Bio is a biotechnology company that develops first-in-class RNA therapeutics targeting U1 snRNP dysfunction to slow tumor evolution, reduce cancer heterogeneity, and overcome adaptive resistance in glioblastoma and s
Aptah Bio | RNA Therapeutics to Slow Cancer Evolution
Very happy to have Rafael M. Bottos of Aptah Bio speak at the upcoming 12th ARDD. And every speaker should use his LinkedIn post as example. ARDD will be epic this year and I could not be more… | Alex Zhavoronkov LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at an
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Aptah Bio | RNA Therapeutics to Slow Cancer Evolution
Aptah Bio | RNA Therapeutics to Slow Cancer Evolution
Aptah Bio | RNA Therapeutics to Slow Cancer Evolution
Aptah Bio | RNA Therapeutics to Slow Cancer Evolution